[RESEARCH BLOG] · 2026-09-02
Telix Pharmaceuticals (TLX) – Phase‑3 BiPASS Completion Triggers **SELL** Signal in Bull Market
By Pierre Brunelle · Founder & Research Lead
Telix Pharmaceuticals Limited closed at $10.85, down 2.16 % on the 2026‑09‑01 US session, a move that sits squarely within the firm’s latest SELL directional signal from LOPJLB. The signal emerges despite a broader bullish market regime, raising questions about the sustainability of TLX’s recent commercial momentum and pipeline progress.
Recent Developments & Catalysts
| Date | Headline |
|---|---|
| 2026‑09‑01 | Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway |
| 2026‑08‑31 | Telix Appoints David Gill as Chair |
| 2026‑08‑24 | Telix Pharmaceuticals: Execution Is The Name Of The Game Here |
| 2026‑08‑20 | Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript |
| 2026‑08‑19 | Telix Pharmaceuticals H1 Earnings Call Highlights |
| 2026‑08‑19 | Telix 2026 Half‑Year Results: Strong Commercial Execution and Momentum in Late‑Stage Pipeline |
| 2026‑08‑05 | Telix to Host R&D Day in New York City on September 22, 2026 |
| 2026‑07‑31 | Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat |
| 2026‑07‑30 | Telix H1 2026 Results: Investor Webcast Notification |
| 2026‑07‑22 | [Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17 % as Wall Street Analysts Expect?](https://www.zacks.com/stock/news/2958171/does-telix-pharmaceuticals-limited-tlx-have-the-potential-to-rally-86-17-as-wall-street-analysts-expect?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape |
These releases collectively highlight the completion of the pivotal BiPASS enrollment, a new chair appointment, strong half‑year commercial execution, and an upcoming R&D Day that together form the primary catalysts for TLX’s near‑term outlook.
Fundamentals and Valuation
Telix’s valuation metrics remain stretched relative to historical averages. The trailing twelve‑month (TTM) P/E ratio sits at 111.4×, while the forward P/E jumps to 169.4×, reflecting market expectations of accelerated earnings growth that have yet to materialize in the income statement. The EV/EBITDA multiple of 126× further underscores the premium investors are paying for the company’s future pipeline potential.
| Metric | Value |
|---|---|
| P/E (TTM) | 111.4 |
| P/E (Forward) | 169.4 |
| EV/EBITDA | 126.0 |
| P/B | 7.42 |
| ROIC | 4.27 % |
| ROE | 7.11 % |
| ROA | 2.40 % |
| Gross Margin | 52.16 % |
| Operating Margin | –0.73 % |
| Net Margin | 3.60 % |
| Debt/Equity | 118.9 % |
The balance sheet reflects a debt‑to‑equity ratio of 118.9 %, indicating a capital structure heavily weighted toward leverage—a point of concern given the modest ROIC of 4.27 %. Nonetheless, the firm’s gross margin of 52.16 % remains respectable for a biopharma with both commercial and R&D spend, while operating margin stays negative at –0.73 %, highlighting ongoing cost pressures.
Revenue growth has accelerated in the most recent reporting period. Telix posted $477 million in Q2 2026 revenue, a 22 % year‑over‑year increase driven primarily by its Precision Medicine segment. This growth follows a 63 % jump in Q1 2025 and a 56 % surge in Q4 2025, illustrating a pattern of double‑digit top‑line expansion over the past two years. However, profitability has been volatile. EBITDA rose 146 % YoY to $52 million, while net profit after tax reached $38 million, a notable improvement from the loss‑making years of 2020‑2022 when the company recorded negative earnings per share (EPS) and deep operating deficits.
The historical financial trajectory underscores a dramatic turnaround. In 2020, Telix generated $5.2 million in revenue with a ‑861.1 % net margin and a ‑56.81 % ROE. By 2024, revenue had swelled to $783 million, margins turned positive (net margin 6.37 %, ROE 8.79 %), and the forward P/E fell to 165.1×. Yet, 2025 saw a dip in earnings, with EPS slipping to ‑0.03 and a ‑0.89 % net margin, prompting a ‑354.8× P/E (negative earnings). The latest quarter’s rebound to positive earnings suggests a possible re‑establishment of profitability, but the volatility remains a red flag for risk‑averse investors.
Analyst consensus assigns a Buy rating with an average price target of $18.00, implying a 66 % upside from the current price. This optimism is anchored in the expectation that TLX will successfully navigate the FDA review for Pixclara (PDUFA date set for September 11) and bring Zircaix back to market after a corrective resubmission. Nonetheless, the SELL directional signal from LOPJLB reflects a composite assessment that weighs the high valuation, leverage, and lingering execution risks against the upside potential.
Earnings Call
During the Q2 2026 earnings call, management emphasized that “EBITDA improved 146 % year‑on‑year to $52 million, and net profit after tax was up to $38 million, reflecting strong business performance and continued control of operating expenditure.” The tone remained stable, with a management sentiment score of +0.60, identical to the level recorded in Q3 2023.
Guidance for the full year was maintained, with the company reiterating its FY 2026 revenue outlook of $950‑$970 million and expressing confidence in achieving the upper end of that range. The call highlighted progress across the pipeline: Pixclara is on track for a September 11 PDUFA decision, Zircaix resubmission is expected within the next 1‑2 months, and BiPASS enrollment completed ahead of schedule, signaling strong physician interest.
Management also addressed execution risks, noting that “We are a pure‑play radiopharmaceutical firm, and our strength is based on five core pillars of activity.” The firm’s commercial strategy, centered on the two‑product launch of Gozellix and Illuccix, was praised: “The launch of Gozellix has been very successful. Demand was strong from day 1, and the adoption we've seen reinforces that our two‑product strategy is delivering exactly what we've intended.” These remarks underscore confidence in the company’s operating model while acknowledging that regulatory timing for Zircaix and Pixclara remains a key catalyst.
LOPJLB Signal Read
The LOPJLB platform currently flags TLX with a SELL directional signal and a ‑5 score, even as the broader market sits in a BULL regime (13‑day HMM). The composite PERF rating stands at 49.00, while the FUND quality score is 16.74, placing the stock in the Balanced archetype (Value = 8.00, Growth = 39.00, GARP = 6.40, Quality = 16.74). These metrics suggest that, despite growth‑oriented fundamentals, the stock’s valuation and quality attributes are not sufficient to outweigh the downside bias in the signal.
Readers are encouraged to explore the interactive chart above on the TLX page for a visual overlay of the signal components, and to review the full methodology at the LOPJLB research methodology page for a deeper understanding of how the signal is derived.
Explore TLX further:
- Detailed stock profile: https://www.lopjlb.com/stock/TLX
- Earnings call transcript and highlights: https://www.lopjlb.com/stock/TLX/earnings.md
- Run a custom screen across our universe: https://www.lopjlb.com/screener
The information presented herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consider their risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.